S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
Critical asset just had biggest fall on record (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

$159.00
+0.34 (+0.21%)
(As of 02/27/2024 ET)
Today's Range
$157.91
$161.31
50-Day Range
$147.00
$198.20
52-Week Range
$143.52
$218.88
Volume
674,827 shs
Average Volume
951,003 shs
Market Capitalization
$20.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$216.12

Alnylam Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.58 Rating Score
Upside/​Downside
35.9% Upside
$216.12 Price Target
Short Interest
Healthy
3.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.52
Upright™ Environmental Score
News Sentiment
0.52mentions of Alnylam Pharmaceuticals in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$5.85 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.73) to ($2.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.79 out of 5 stars

Medical Sector

46th out of 944 stocks

Pharmaceutical Preparations Industry

13th out of 406 stocks


ALNY stock logo

About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Stock Price History

ALNY Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $225.00
ALNY Mar 2024 130.000 put
Q4 2023 Alnylam Pharmaceuticals Inc Earnings Call
See More Headlines
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
2/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$216.12
High Stock Price Target
$395.00
Low Stock Price Target
$161.00
Potential Upside/Downside
+35.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.58
Research Coverage
19 Analysts

Profitability

Net Income
$-440,240,000.00
Pretax Margin
-23.71%

Debt

Sales & Book Value

Annual Sales
$1.83 billion
Book Value
($1.76) per share

Miscellaneous

Free Float
124,183,000
Market Cap
$20.03 billion
Optionable
Optionable
Beta
0.43

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives















ALNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Alnylam Pharmaceuticals stock right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 8 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALNY shares.
View ALNY analyst ratings
or view top-rated stocks.

What is Alnylam Pharmaceuticals' stock price target for 2024?

19 brokers have issued 12-month price objectives for Alnylam Pharmaceuticals' stock. Their ALNY share price targets range from $161.00 to $395.00. On average, they predict the company's stock price to reach $216.12 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price.
View analysts price targets for ALNY
or view top-rated stocks among Wall Street analysts.

How have ALNY shares performed in 2024?

Alnylam Pharmaceuticals' stock was trading at $191.41 on January 1st, 2024. Since then, ALNY shares have decreased by 16.9% and is now trading at $159.00.
View the best growth stocks for 2024 here
.

When is Alnylam Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALNY earnings forecast
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.10. The biopharmaceutical company had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. The firm's quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.68) EPS.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Capital World Investors (12.89%), Vanguard Group Inc. (9.52%), Baillie Gifford & Co. (5.55%), Dodge & Cox (2.92%), Capital International Investors (2.86%) and Price T Rowe Associates Inc. MD (2.78%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends
.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALNY) was last updated on 2/28/2024 by MarketBeat.com Staff